(firstQuint)Combination of Rituximab and NK Immunotherapy for B Lymphoma.

 By enrolling patients with B lymphoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Rituximab and natural killer (NK) cells.

 The safety will be evaluated by statistics of adverse reactions.

 The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

.

 Combination of Rituximab and NK Immunotherapy for B Lymphoma@highlight

The aim of this study is the safety and efficacy of Rituximab plus NK immunotherapy to recurrent B lymphoma.

